In summary, our study indicates that genetic and pharmacological inhibition of GCN2 alleviates hyperglycemia and insulin resistance in T2D mice by regulating hepatic glucose metabolism and attenuating hepatic steatosis and oxidative stress. This evidence concerns the gene EIF2AK4 and type 2 diabetes mellitus.